Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
Current treatment of patients with coronavirus 2019 (COVID-19) involves repurposed drugs that inhibit viral infection by either binding to their respective targets or via modulating cellular signal transduction. However, there is still a great deal of efficacy enhancement through combination therapy...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12533
- Acceso en línea:
- https://doi.org/10.1016/j.drudis.2020.08.002
http://hdl.handle.net/20.500.12010/12533
- Palabra clave:
- COVID-19
Remdesivir
Hydroxychloroquine
Chloroquine
Favipiravir
Ribavirin
Umifenovir
Lopinavir
Ritonavir
Tocilizumab
Sarilumab
Camostat
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Acceso restringido